Cytisine in the treatment of tobacco dependence: safety, efficacy, market in Eastern Europe
More details
Hide details
Health Promotion Foundation, Poland
Submission date: 2016-03-30
Acceptance date: 2016-03-31
Publication date: 2016-03-31
Corresponding author
Aleksandra Herbec   

Health Promotion Foundation, Poland, ul. Sobieskiego 110/7, PL-00-764 Warsaw, Poland
Tob. Prev. Cessation 2016;2(April Supplement):22
Cytisine is a generic partial agonist of nicotine receptors α4β2 that has been available in Eastern Europe since 1960s. Through decades of observations and clinical studies, with much research conducted in Poland, cytisine has been shown to be safe and highly cost-effective medication in treatment for tobacco dependence, with a profile potentially more favourable than that of varenicline. Poland remains among few European countries allowing for sales of cytisine. Currently, cytisine-based treatment is available over-the counter in Poland, where it is the dominant form of cessation pharmacotherapy. This presentation will outline the current state of knowledge on cytisine, as well as discuss the observations on sales and use of cytisine in treatment of smoking cessation in Poland. A case will be made for cytisine emerging as an ‘aspirin’ in smoking cessation, and an important element of future tobacco control worldwide.
Journals System - logo
Scroll to top